What question did this study set out to answer?

To evaluate whether combined-modality treatment with two cycles of ABVD chemotherapy plus extended-field radiotherapy provides superior tumor control compared to extended-field radiotherapy alone in early favorable Hodgkin lymphoma.

July 3, 2007Journal of Clinical OncologyOpen Access

Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial

View Full Paper

Ask AI

Bookmark

Authors

AEAndreas EngertNorthwestern University JFJeremy FranklinUniversity of Cologne HEHans Theodor EichUniversity of Münster

Discussion

Member takes

Implication

Randomized trial demonstrates adding ABVD chemotherapy to radiotherapy reduces relapse in early favorable Hodgkin lymphoma, indicating the superiority of combined-modality treatment.

Key Points

To evaluate whether combined-modality treatment with two cycles of ABVD chemotherapy plus extended-field radiotherapy provides superior tumor control compared to extended-field radiotherapy alone in early favorable Hodgkin lymphoma.
Multicenter randomized trial enrolling 650 patients between 1993 and 1998 with newly diagnosed clinical stage IA to IIB Hodgkin lymphoma without risk factors.
Patients were randomly assigned to either 30 Gy extended-field radiotherapy with a 10 Gy involved-field boost (arm A) or two cycles of ABVD followed by the same radiotherapy regimen (arm B), with a median follow-up of 87 months.
Seven-year freedom from treatment failure was significantly higher in arm B at 88% (95% CI, 84% to 92%) compared to 67% in arm A (95% CI, 61% to 73%; P <= .0001), reflecting a substantial reduction in relapses (3% vs 22%).
Seven-year overall survival was 94% in arm B versus 92% in arm A (P = .43), and complete response rates were 94% and 95%, respectively.
A total of 39 second malignancies developed (18 in arm B and 21 in arm A; annual incidence ~0.8%), occurring more frequently in older patients (P < .0001) and those with B symptoms (P = .012).

Cite This Study

Engert et al. (2007) studied this question.

synapsesocial.com/papers/6a86c616bb0787ff27ca0704 https://doi.org/10.1200/jco.2006.07.0482

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates adding ABVD chemotherapy to radiotherapy reduces relapse in early favorable Hodgkin lymphoma, indicating the superiority of combined-modality treatment.

Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider